1). Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011; 24:275–83.
Article
2). Irish BP, Khan ZK, Jain P, Nonnemacher MR, Pirrone V, Rahman S, et al. Molecular mechanisms of neuro-degenerative diseases induced by human retroviruses: a review. Am J Infect Dis. 2009; 5:231–58.
Article
3). Wright E. Neurocognitive impairment and neuroCART. Curr Opin HIV AIDS. 2011; 6:303–8.
Article
4). Romani B, Engelbrecht S, Glashoff RH. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol. 2010; 91:1–12.
Article
5). Kaul M, Lipton SA. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res. 2006; 4:307–18.
Article
6). Khiati A, Chaloin O, Muller S, Tardieu M, Horellou P. Induction of monocyte chemoattractant protein-1 (MCP-1/CCL2) gene expression by human immunodeficiency virus-1 Tat in human astrocytes is CDK9 dependent. J Neurovirol. 2010; 16:150–67.
Article
7). Turchan-Cholewo J, Dimayuga VM, Gupta S, Gorospe RM, Keller JN, Bruce-Keller AJ. NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxid Redox Signal. 2009; 11:193–204.
8). Williams R, Yao H, Peng F, Yang Y, Bethel-Brown C, Buch S. Cooperative induction of CXCL10 involves NADPH oxidase: implications for HIV dementia. Glia. 2010; 58:611–21.
Article
9). Del Valle L, Croul S, Morgello S, Amini S, Rappaport J, Khalili K. Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol. 2000; 6:221–8.
Article
10). Yoon CH, Woo JY, Bae YS. HIV-1 Infection causes intracellular expression of p53, which induces PKR expression, followed by inhibition of HIV-1 Tat activity. J Bacteriol Virol. 2004; 34:157–66.
11). Kalantari P, Narayan V, Henderson AJ, Prabhu KS. 15-Deoxy-Delta12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification. FASEB J. 2009; 23:2366–73.
12). Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140:918–34.
Article
13). Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res. 2010; 33:1539–56.
Article
14). Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem. 2006; 281:20315–25.
15). Lee EO, Kim SE, Park HK, Kang JL, Chong YH. Extracellular HIV-1 Tat upregulates TNF-α dependent MCP-1/CCL2 production via activation of ERK1/2 pathway in rat hippocampal slice cultures: Inhibition by resveratrol, a polyphenolic phytostilbene. Exp Neurol. 2011; 229:399–408.
Article
16). Holopainen IE. Organotypic hippocampal slice cultures: a model system to study basic cellular and molecular mechanisms of neuronal cell death, neuroprotection, and synaptic plasticity. Neurochem Res. 2005; 30:1521–8.
Article
17). Manzoor Z, Koh YS. Mitogen-activated protein kinases in inflammation. J Bacteriol Virol. 2012; 42:189–95.
Article
18). Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004; 303:1483–7.
19). Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci. 2006; 119:395–402.
Article
20). Sharma A, Hu XT, Napier TC, Al-Harthi L. Methamphetamine and HIV-1 Tat down regulate β-catenin signaling: implications for methampetamine abuse and HIV-1 co-morbidity. J Neuroimmune Pharmacol. 2011; 6:597–607.
Article
21). Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology. 2006; 27:217–28.
Article
22). Aksenova MV, Aksenov MY, Adams SM, Mactutus CF, Booze RM. Neuronal survival and resistance to HIV-1 Tat toxicity in the primary culture of rat fetal neurons. Exp Neurol. 2009; 215:253–63.
Article
23). Kruman II, Nath A, Mattson MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol. 1998; 154:276–88.
Article
24). Brailoiu GC, Brailoiu E, Chang JK, Dun NJ. Excitatory effects of human immunodeficiency virus 1 Tat on cultured rat cerebral cortical neurons. Neuroscience. 2008; 151:701–10.
Article
25). Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, et al. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol. 1996; 70:1475–80.
Article
26). Brana C, Biggs TE, Mann DA, Sundstrom LE. A macrophage hippocampal slice co-culture system: application to the study of HIV-induced brain damage. J Neurosci Methods. 1999; 90:7–11.
Article
27). Yao H, Peng F, Dhillon N, Callen S, Bokhari S, Stehno-Bittel L, et al. Involvement of TRPC channels in CCL2-mediated neuroprotection against tat toxicity. J Neurosci. 2009; 29:1657–69.
Article
28). Yao H, Peng F, Fan Y, Zhu X, Hu G, Buch SJ. TRPC channel-mediated neuroprotection by PDGF involves Pyk2/ERK/CREB pathway. Cell Death Differ. 2009; 16:1681–93.
Article
29). Zhu X, Yao H, Peng F, Callen S, Buch S. PDGF-mediated protection of SH-SY5Y cells against Tat toxin involves regulation of extracellular glutamate and intracellular calcium. Toxicol Appl Pharmacol. 2009; 240:286–91.
Article
30). Shi J, Qin X, Zhao L, Wang G, Liu C. Human immunodeficiency virus type 1 Tat induces B7-H1 expression via ERK/MAPK signaling pathway. Cell Immunol. 2011; 271:280–5.
Article
31). Appel S, Mirakaj V, Bringmann A, Weck MM, Grünebach F, Brossart P. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood. 2005; 106:3888–94.
32). Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists. Kidney Int. 2004; 65:2081–90.
33). Alvarez-Maqueda M, El Bekay R, Alba G, Monteseirín J, Chacón P, Vega A, et al. 15-Deoxy-Δ12,14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes. J Biol Chem. 2004; 279:21929–37.
34). Kim DH, Kim JH, Kim EH, Na HK, Cha YN, Chung JH, et al. 15-Deoxy-Delta12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. Carcinogenesis. 2009; 30:645–54.
35). Chiba T, Ueki S, Ito W, Kato H, Takeda M, Kayaba H, et al. 15-Deoxy-Δ(12,14)-prostaglandin J2 induces IL-8 and GM-CSF in a human airway epithelial cell line (NCI-H292). Int Arch Allergy Immunol. 2009; 149:77–82.
36). Wilmer WA, Dixon C, Lu L, Hilbelink T, Rovin BH. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARγ. Biochem Biophys Res Commun. 2001; 281:57–62.
Article
37). Qin S, McLaughlin AP, De Vries GW. Protection of RPE cells from oxidative injury by 15-deoxydelta12,14-prostaglandin J2 by augmenting GSH and activating MAPK. Invest Ophthalmol Vis Sci. 2006; 47:5098–105.
38). Kim EH, Na HK, Surh YJ. Upregulation of VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. Ann N Y Acad Sci. 2006; 1090:375–84.